Conflict of Interest
Oncocyte
EMD
Michael S. Wertheim served on the speakers’ bureau for AstraZeneca, Celgene, and Millennium. Edward J. Kim reports consulting or advisory role at Eisai and served on the scientific advisory board for Taiho, as well as research funding from Bristol Myers Squibb, Astellas, Merck, Eureka Therapeutics, NGM Biopharmaceuticals, Fibrogen, Erytech, AstraZeneca, Medimmune, and Beigene. Benjamin Tan reports institutional research funding from Adaptimmune, Agios, AstraZeneca, Bristol Myers Squibb, Eisai, Exelexis, Merck, Roche/Genentech, Tyme, and Zymeworks. Heinz-Josef Lenz served on the advisory board for Bayer, Bristol Myers Squibb, Fulgent, Merck, MSD, Roche, and Oncocyte. Andreas Machl reports employment with EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA. Genevieve Jehl and Rena Ito report employment with Merck. James L. Gulley reports that his institute has a Cooperative Research and Development Agreement (CRADA) with Merck, and he is a co-primary investigator on this CRADA but has no personal financial interests and is an unpaid member of the expert oncology faculty that advises Merck. Scott Kopetz reports consulting or advisory role at Amgen, Roche, Bayer HealthCare Pharmaceuticals, Array BioPharma, Merck, Genentech, Symphogen, MSD, Holy Stone, Novartis, Lilly, Boehringer Ingelheim, Boston Biomedical, AstraZeneca/MedImmune, Pierre Fabre, Redx Pharma, Ipsen, Daiichi Sankyo, Natera, HalioDx, Lutris, Jacobio, Pfizer, Repare Therapeutics, Inivata, GlaxoSmithKline, Jazz Pharmaceuticals, Iylon, Xilis, Abbvie, Amal Therapeutics, Gilead Sciences, Mirati Therapeutics, Flame Biosciences, Servier, Carina Biotechnology, Bicara Therapeutics, Endeavor BioMedicines, Numab Pharma, Johnson & Johnson/Janssen, and Karyopharm Therapeutics; institutional research funding from Amgen, Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech/Roche, Merck, MSD, MedImmune, Lilly, Daiichi Sankyo, and Novartis; and ownership interest in MolecularMatch, Lutris, and Iylon. The other authors indicated no financial relationships.